Shares of Arizona-based Axon Enterprise, Inc. (AXON) gained up to 22.
Oppenheimer’s Jay Olson finds it encouraging to see AXON evolving its pipeline to gene therapy.
It’s a very rewarding trading day for investors in Axovant Sciences (NASDAQ:AXON) with shares up nearly 115%, making the stock Wall Street’s bull …
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …
A tale of two beaten biotech stocks: GNCA, AXON.
Pivotal phase 3 MINDSET trial fails, AD program discontinued, Oppenheimer moves to sidelines.
Healthcare analysts share two cents on two falling biotech stocks.
Axovant Sciences Ltd (NASDAQ:AXON) investors hit the panic button after the dementia drug maker announced that the Phase 3 MINDSET clinical trial of its investigational …
Synaptics Incorporated Top Oppenheimer analyst Andrew Uerkwitz has downgraded his rating on shares of Syros Pharmaceuticals Inc (NASDAQ:SYNA) to Sell – his first …
Axovant Sciences Ltd (NYSE:AXON) shares are falling nearly 12% following the news that Lundbeck’s experimental Alzheimer’s drug Idalopirdine failed in a late-stage study. …